Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
31 okt 2014 - 08:23
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Dr Inge Lues joins Probiodrug Management Board as Chief Development Officer
Bericht
Dr Inge Lues joins Probiodrug Management Board as Chief Development Officer
HALLE/SAALE, Germany, 31 October 2014 - Probiodrug AG ("Probiodrug", Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's Disease, announces that on September 30, 2014, the Supervisory Board of Probiodrug appointed Dr Inge Lues as member of the Management Board as Chief Development Officer effective November 1, 2014.
Dr Lues joined Probiodrug as R&D advisor in 2008 and has acted as Chief Development Officer since 2013. As a member of the Management Board she will be responsible for all research and development activities of Probiodrug
Gerelateerde downloads
Datum laatste update: 27 juli 2024